A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 2, 2007, Pages 743-752

  Rivera, Noelia ^a   Everett Grueter, Carrie A ^a   Edgerton, Dale S ^a   Rodewald, Tiffany ^a   Neal, Doss W ^a   Nishimura, Erica ^b   Larsen, Marianne O ^b   Jacobsen, Lene O ^b   Kristensen, Kim ^b   Brand, Christian L ^b   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON RECEPTOR ANTAGONIST; GLUCOSE; INSULIN; NNC 25 0926; RECEPTOR BLOCKING AGENT; SOMATOSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; GLUCONEOGENESIS; GLYCOGENOLYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

ANILINE COMPOUNDS; ANIMALS; BETA-ALANINE; C-PEPTIDE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCONEOGENESIS; GLUCOSE; GLYCOGENOLYSIS; LIVER; MALE; RECEPTORS, GLUCAGON;

EID: 34247237309     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.115717     Document Type: Article

References (40)

1. Basu R, Schwenk WF, and Rizza RA (2004a) Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes. Am J Physiol 287:E55-E62.
2. Basu A, Shah P, Nielsen M, Basu R, and Rizza RA (2004b) Effects of type 2 diabetes on the regulation of hepatic glucose metabolism. J Investig Med 52:366-374.
3. Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, and Holst JJ (1994) Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37:985-993.
4. Burcelin R, Katz EB, and Charron MJ (1996) Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. Diabetes Metab 22:373-396.
5. Cherrington AD (1999) Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48:1198-1214.
6. Cherrington AD, Liljenquist JE, Shulman GI, Williams PE, and Lacy WW (1979) Importance of hypoglycemia-induced glucose production during isolated glucagon deficiency. Am J Physiol 236:E263-E271.
7. Cherrington AD, Williams PE, Shulman GI, and Lacy WW (1981) Differential time course of glucagon's effect on glycogenolysis and gluconeogenesis in the conscious dog. Diabetes 30:180-187.
8. Chu CA, Sindelar DK, Neal DW, Allen EJ, Donahue EP, and Cherrington AD (1997) Comparison of the direct and indirect effects of epinephrine on hepatic glucose production. J Clin Investig 99:1044-1056.
9. Consoli A, Nurjhan N, Reilly JJ Jr, Bier DM, and Gerich JE (1990) Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism. J Clin Investig 86:2038-2045.
10. Dobbins RL, Davis SN, Neal DW, Cobelli C, and Cherrington AD (1994) Pulsatility does not alter the response to a physiological increment in glucagon in the conscious dog. Am J Physiol 266:E467-E478.
11. Dobbins RL, Davis SN, Neal DW, Cobelli C, Jaspan J, and Cherrington AD (1995) Compartmental modeling of glucagon kinetics in the conscious dog. Metabolism 44:452-459.
12. Edgerton DS, Cardin S, Neal D, Farmer B, Lautz M, Pan C, and Cherrington AD (2004) Effects of hyperglycemia on hepatic gluconeogenic flux during glycogen phosphorylase inhibition in the conscious dog. Am J Physiol 286:E510-E522.
13. Flattem N, Igawa K, Shiota M, Emshwiller MG, Neal DW, and Cherrington AD (2001) alpha- and beta-Cell responses to small changes in plasma glucose in the conscious dog. Diabetes 50:367-375.
14. Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, Landau BR, and Ferrannini E (2000) Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49:1367-1373.
15. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, et al. (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 100:1438-1443.
16. 125I)-lactoperoxidase technique. Biochem Biophys Res Commun 67:43-49.
17. Gravholt CH, Moller N, Jensen MD, Christiansen JS, and Schmitz O (2001) Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. J Clin Endocrinol Metab 86:2085-2089.
18. Jensen MD, Heiling VJ, and Miles JM (1991) Effects of glucagon on free fatty acid metabolism in humans. J Clin Endocrinol Metab 72:308-315.
19. Jiang G and Zhang BB (2003) Glucagon and regulation of glucose metabolism. Am J Physiol 284:E671-E678.
20. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, She P, Jetton TL, and Demarest KT (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53: 410-417.
21. Ling A, Plewe M, Gonzalez J, Madsen P, Sams CK, Lau J, Gregor V, Murphy D, Teston K, Kuki A, et al. (2002) Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg Med Chem Lett 12:663-666.
22. Lloyd B, Burrin J, Smythe P, and Alberti KG (1978) Enzymic fluorometric continuous-flow assays for blood glucose, lactate, pyruvate, alanine, glycerol, and 3-hydroxybutyrate. Clin Chem 24:1724-1729.
23. Mari A (1992) Estimation of the rate of appearance in the non-steady state with a two-compartment model. Am J Physiol 263:E400-E415.
24. McConahey PJ and Dixon FJ (1980) Radioiodination of proteins by the use of the chloramine-T method. Methods Enzymol 70:210-213.
25. McGuinness OP, Burgin K, Moran C, Bracy D, and Cherrington AD (1994) Role of glucagon in the metabolic response to stress hormone infusion in the conscious dog. Am J Physiol 266:E438-E447.
26. Moore MC, Pagliassotti MJ, Swift LL, Asher J, Murrell J, Neal D, and Cherrington AD (1994) Disposition of a mixed meal by the conscious dog. Am J Physiol 266:E666-E675.
27. Morgan CR and Lazarow A (1962) Immunoassay of insulin using a two-antibody system. Proc Soc Exp Biol Med 110:29-32.
28. Myers SR, McGuinness OP, Neal DW, and Cherrington AD (1991) Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration. J Clin Investig 87:930-939.
29. Nishimura E, Winzel MS, Brand CL, and Ahrén BO (2006) Treatment with a glucagon receptor antagonist improves B-cell function, insulin sensitivity and glucose metabolism in mice with high-fat diet-induced insulin resistance. Diabetes 55:A346.
30. Parker JC, McPherson RK, Andrews KM, Levy CB, Dubins JS, Chin JE, Perry PV, Hulin B, Perry DA, Inagaki T, et al. (2000) Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes 49:2079-2086.
31. Petersen KF and Sullivan JT (2001) Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44:2018-2024.
32. Pilkis SJ and Granner DK (1992) Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 54:885-909.
33. Puhakainen I, Koivisto VA, and Yki-Jarvinen H (1992) Lipolysis and gluconeogenesis from glycerol are increased in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 75:789-794.
34. Qureshi SA, Rios Candelore M, Xie D, Yang X, Tota LM, Ding VD, Li Z, Bansal A, Miller C, Cohen SM, et al. (2004) A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 53:3267-3273.
35. Raju B and Cryer PE (2005) Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? Am J Physiol 289:E181-E186.
36. Ravier MA and Rutter GA (2005) Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. Diabetes 54:1789-1797.
37. Shah P, Vella A, Basu A, Basu R, Schwenk WF, and Rizza RA (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059.
38. Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL, Jacobs SJ, Moyers JS, Owens RA, Showalter AD, et al. (2004) Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Investig 113:1571-1581.
39. Unson CG, Gurzenda EM, and Merrifield RB (1989) Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist. Peptides 10:1171-1177.
40. Young A (2005) Inhibition of glucagon secretion. Adv Pharmacol 52:151-171.